Lumida
/CRVS
⌘K
Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

CRVS
$14.90USD↑+4.41%+0.63 today

MARKET CAP

1.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $15

52W RANGE

$4
$27

AI Summary

Stalk
Buy NowMedium

A Stage 2 advancing context persists with a clear Lockout Rally driving forced participation above rising 9EMA, 20EMA, and 50DMA. Price is extended but the Lockout Rally override supports continued upside without typical exhaustion constraints. Medium- and short-term biases align bullish, presenting favorable conditions for Buy Now. Key risks include a deep pullback breaching EMA support and moderate transition risk toward Stage 3.

  • ↑Phase I atopic dermatitis Cohort 3 yielded a 64.8% EASY score reduction vs. 40% placebo.
  • ↑Raised $189 M via public offering; cash balance $56.8 M funds operations into 2026.
  • ↓Q4 2025 R&D expenses rose to $9.9 M, driving net loss to $12.3 M.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Corvus Pharmaceuticals (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company engaged in developing innovative therapies targeting cancer and autoimmune diseases. Its lead asset, soqualitinib, a selective ITK inhibitor, is focused on conditions such as atopic dermatitis and relapsed peripheral T-cell lymphoma (PTCL). Corvus is strategically positioned in the rapidly evolving healthcare market, with ambitions to address significant unmet medical needs through its promising pipeline of immuno-oncology therapies.

Bull says

  • ↑Phase I atopic dermatitis Cohort 3 yielded a 64.8% EASY score reduction vs. 40% placebo.
  • ↑Raised $189 M via public offering; cash balance $56.8 M funds operations into 2026.
  • ↑Directors bought shares and high 13F ownership signals strong institutional backing.
  • ↑Planning Phase II asthma and hidradenitis suppurativa trials to diversify pipeline.
  • ↑Strong momentum factors and positive liquidity support trading demand despite current downturn.
  • ↑Selective ITK inhibitor mechanism could differentiate soqualitinib across oncology and immunology.

Bear says

  • ↓Q4 2025 R&D expenses rose to $9.9 M, driving net loss to $12.3 M.
  • ↓Negative earnings yield indicates unprofitable operations and possible overvaluation.
  • ↓Small sample size in Cohort 3 adds execution risk for pivotal trials.
  • ↓Dependence on Angel Pharmaceuticals partnership for China exposes market entry risk.
  • ↓High leverage and weak profitability factors highlight balance sheet vulnerabilities.
  • ↓Negative growth and revisions factors increase potential for downward stock pressure.

Investment themes with CRVS

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 07-14-2026bullish

Transcript signals

Bull points

  • As of December 31, 2024, Corvus had cash, cash equivalents, and marketable securities totaling $52 million as compared to $27.1 million at December 31, 2023.
  • Two investors early exercised their warrants during the fourth quarter of 2024, resulting in $18.6 million in cash to the company. If all the remaining warrants are exercised, we will receive approximately $41 million in additional cash.
  • Based on our current plans, we anticipate our cash provides runway into the first quarter of 2026.

Bear points

  • The net loss for the fourth quarter 2024 was $12.1 million, including a non-cash loss of $2.2 million related to Angel Pharmaceuticals, our partner in China.
  • The net loss for the full year 2024 was $63.3 million, including a $3.2 million non-cash loss related to Angel and a non-cash loss of $33.4 million from the change in fair value of Corvus' warrant liability during the year.
  • We have deliberately searched for sicker patients in cohort three. So we do have more Dupixent and systemic treatment failures in cohort three.
Read full transcript analysis ›